StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN – Get Rating) in a research report report published on Thursday morning. The brokerage issued a sell rating on the medical research company’s stock.
OpGen Stock Performance
Shares of OpGen stock opened at $1.47 on Thursday. The firm has a fifty day moving average of $1.61 and a two-hundred day moving average of $0.75. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.05 and a current ratio of 1.11. The stock has a market capitalization of $3.94 million, a price-to-earnings ratio of -0.08 and a beta of -0.22. OpGen has a 52 week low of $0.93 and a 52 week high of $17.90.
Institutional Investors Weigh In On OpGen
Several hedge funds have recently bought and sold shares of OPGN. Armistice Capital LLC acquired a new position in OpGen in the third quarter valued at about $1,517,000. Vanguard Group Inc. raised its holdings in shares of OpGen by 39.8% during the third quarter. Vanguard Group Inc. now owns 1,877,597 shares of the medical research company’s stock worth $537,000 after acquiring an additional 534,960 shares during the period. HRT Financial LP bought a new stake in OpGen in the 4th quarter valued at $26,000. Citadel Advisors LLC boosted its stake in OpGen by 571.0% in the 3rd quarter. Citadel Advisors LLC now owns 100,773 shares of the medical research company’s stock worth $29,000 after purchasing an additional 85,754 shares during the period. Finally, FNY Investment Advisers LLC bought a new position in OpGen during the 4th quarter worth about $232,000. 16.36% of the stock is currently owned by institutional investors and hedge funds.
OpGen Company Profile
OpGen, Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It engages in the development of molecular information products and services for global healthcare settings. The firm’s also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms.
- Get a free copy of the StockNews.com research report on OpGen (OPGN)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.